Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis
David Jayne(University of Cambridge), Annette Bruchfeld(Karolinska University Hospital), Michael Venning(Manchester Royal Infirmary), Volker Burst(University Hospital Cologne), Pirow Bekker(ChemoCentryx (United States)), Mårten Segelmark(Lund University), Patrick Hamilton(Manchester Royal Infirmary), Lorraine Harper(University Hospitals Birmingham NHS Foundation Trust), Michel Jadoul(Cliniques Universitaires Saint-Luc), Antonia Potarca(ChemoCentryx (United States)), István Szombati(Royal Irgalmasrendi Hospital), Franziska Grundmann(University Hospital Cologne), Thomas J. Schall(ChemoCentryx (United States)), Matthias Schaier(Heidelberg University), Vladimı́r Tesař(Charles University)
Cited by 599
Related Papers
Identification of a major co-receptor for primary isolates of HIV-1
|Nature|1996|3.7k
A new class of membrane-bound chemokine with a CX3C motif
|Nature|1997|2k
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
|New England Journal of Medicine|2010|1.7k